269 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Rank Status Study
1 No longer available Fosamprenavir Expanded Access
Condition: HIV Infection
Interventions: Drug: fosamprenavir;   Drug: Telzir®
2 Available Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,
Condition: HIV
Intervention: Behavioral: Lifestyle Counseling
3 No longer available Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
Condition: Metastatic Renal Cell Cancer
Intervention: Drug: Everolimus
4 Unknown  A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema
Condition: Diabetic Macular Edema
Intervention: Drug: Macugen (Pegaptanib Sodium)
5 Approved for marketing Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: Iobenguane I 123 Injection
6 No longer available HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency
Conditions: Wound; Rupture, Surgery, Cesarean Section;   Postpartum Hemorrhage;   Surgery
Intervention: Biological: Hemoleven
7 Approved for marketing SynCardia Freedom Driver System Study
Condition: Biventricular Failure
Intervention: Device: CardioWest temporary Total Artificial Heart (TAH-t) System
8 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
9 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
10 Unknown  Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
11 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
12 Approved for marketing A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Condition: Gastrointestinal Neoplasm
Intervention: Drug: Sutent
13 Unknown  Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain
Conditions: Chronic Low Back Pain;   Acupuncture
Intervention: Device: Acupuncture, Pak-sham needle
14 Approved for marketing BMN 110 US Expanded Access Program
Conditions: Mucopolysaccharidosis IVA;   Morquio A Syndrome;   MPS IVA
Intervention: Drug: BMN 110
15 No longer available This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma
Intervention: Drug: Plerixafor
16 Unknown  Special Access for the Use of Voclosporin for Kidney Transplantation
Conditions: Kidney Transplantation;   Immunosuppression
Intervention: Drug: Voclosporin
17 Available Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
18 Available Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: Pirfenidone
19 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
20 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years